BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

943 related articles for article (PubMed ID: 20940416)

  • 21. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.
    Rodríguez A; Martínez N; Camacho FI; Ruíz-Ballesteros E; Algara P; García JF; Menárguez J; Alvaro T; Fresno MF; Solano F; Mollejo M; Martin C; Piris MA
    Clin Cancer Res; 2004 Oct; 10(20):6796-806. PubMed ID: 15501956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70.
    Gladkikh AA; Potashnikova DM; Tatarskiy V; Yastrebova M; Khamidullina A; Barteneva N; Vorobjev I
    Cancer Med; 2017 Dec; 6(12):2984-2997. PubMed ID: 29125235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
    Cui B; Chen L; Zhang S; Mraz M; Fecteau JF; Yu J; Ghia EM; Zhang L; Bao L; Rassenti LZ; Messer K; Calin GA; Croce CM; Kipps TJ
    Blood; 2014 Jul; 124(4):546-54. PubMed ID: 24914134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
    Herndon TM; Chen SS; Saba NS; Valdez J; Emson C; Gatmaitan M; Tian X; Hughes TE; Sun C; Arthur DC; Stetler-Stevenson M; Yuan CM; Niemann CU; Marti GE; Aue G; Soto S; Farooqui MZH; Herman SEM; Chiorazzi N; Wiestner A
    Leukemia; 2017 Jun; 31(6):1340-1347. PubMed ID: 28074063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.
    ten Hacken E; Burger JA
    Clin Cancer Res; 2014 Feb; 20(3):548-56. PubMed ID: 24323900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
    Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
    Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-κB pathway.
    Meijers RWJ; Muggen AF; Leon LG; de Bie M; van Dongen JJM; Hendriks RW; Langerak AW
    Haematologica; 2020 Jan; 105(1):182-192. PubMed ID: 31097630
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
    Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.
    Asslaber D; Wacht N; Leisch M; Qi Y; Maeding N; Hufnagl C; Jansko B; Zaborsky N; Villunger A; Hartmann TN; Greil R; Egle A
    Clin Cancer Res; 2019 Mar; 25(6):1901-1912. PubMed ID: 30487125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
    Slinger E; Thijssen R; Kater AP; Eldering E
    Leukemia; 2017 Dec; 31(12):2601-2607. PubMed ID: 28462919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
    Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
    Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.
    Blix ES; Irish JM; Husebekk A; Delabie J; Forfang L; Tierens AM; Myklebust JH; Kolstad A
    BMC Cancer; 2012 Oct; 12():478. PubMed ID: 23072591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.
    Chen Z; Simon-Molas H; Cretenet G; Valle-Argos B; Smith LD; Forconi F; Schomakers BV; van Weeghel M; Bryant DJ; van Bruggen JAC; Peters FS; Rathmell JC; van der Windt GJW; Kater AP; Packham G; Eldering E
    Blood; 2022 Aug; 140(6):630-643. PubMed ID: 35486832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1.
    Gilling CE; Mittal AK; Chaturvedi NK; Iqbal J; Aoun P; Bierman PJ; Bociek RG; Weisenburger DD; Joshi SS
    Br J Haematol; 2012 Jul; 158(2):216-231. PubMed ID: 22571278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia.
    Liso V; Capalbo S; Lapietra A; Pavone V; Guarini A; Specchia G
    Haematologica; 1999 Mar; 84(3):212-7. PubMed ID: 10189384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation.
    Rodríguez A; Villuendas R; Yáñez L; Gómez ME; Díaz R; Pollán M; Hernández N; de la Cueva P; Marín MC; Swat A; Ruiz E; Cuadrado MA; Conde E; Lombardía L; Cifuentes F; Gonzalez M; García-Marco JA; Piris MA;
    Leukemia; 2007 Sep; 21(9):1984-91. PubMed ID: 17611561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
    Dal Bo M; D'Agaro T; Gobessi S; Zucchetto A; Dereani S; Rossi D; Zaja F; Pozzato G; Di Raimondo F; Gaidano G; Laurenti L; Del Poeta G; Efremov DG; Gattei V; Bomben R
    Oncotarget; 2015 Aug; 6(22):19102-17. PubMed ID: 26036258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.